Moors & Cabot’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $303K | Buy |
1,653
+154
| +10% | +$28.4K | 0.01% | 698 |
|
|
2025
Q4 | $264K | Buy |
+1,499
| New | +$245K | 0.01% | 741 |
|
|
2025
Q1 | – | Sell |
-1,335
| Closed | -$204K | – | 883 |
|
|
2024
Q4 | $204K | Buy |
1,335
+215
| +19% | +$36.3K | 0.01% | 807 |
|
|
2024
Q3 | $217K | Sell |
1,120
-10
| -0.9% | -$2.09K | 0.01% | 762 |
|
|
2024
Q2 | $262K | Buy |
1,130
+115
| +11% | +$25K | 0.01% | 672 |
|
|
2024
Q1 | $219K | Buy |
1,015
+73
| +8% | +$17.1K | 0.01% | 787 |
|
|
2023
Q4 | $244K | Buy |
942
+131
| +16% | +$32.2K | 0.02% | 691 |
|
|
2023
Q3 | $208K | Buy |
+811
| New | +$217K | 0.01% | 734 |
|
|
2021
Q3 | – | Sell |
-635
| Closed | -$220K | – | 869 |
|
|
2021
Q2 | $220K | Sell |
635
-95
| -13% | -$28.8K | 0.02% | 702 |
|
|
2021
Q1 | $205K | Buy |
+730
| New | +$197K | 0.02% | 676 |
|
|
2020
Q4 | – | Sell |
-888
| Closed | -$252K | – | 744 |
|
|
2020
Q3 | $252K | Buy |
888
+85
| +11% | +$23.7K | 0.02% | 523 |
|
|
2020
Q2 | $214K | Buy |
+803
| New | +$241K | 0.02% | 559 |
|
|
2020
Q1 | – | Sell |
-913
| Closed | -$273K | – | 603 |
|
|
2019
Q4 | $273K | Sell |
913
-270
| -23% | -$74.9K | 0.03% | 485 |
|
|
2019
Q3 | $275K | Buy |
1,183
+105
| +10% | +$24.4K | 0.03% | 473 |
|
|
2019
Q2 | $252K | Hold |
1,078
| – | – | 0.03% | 456 |
|
|
2019
Q1 | $255K | Buy |
1,078
+195
| +22% | +$61.4K | 0.03% | 433 |
|
|
2018
Q4 | $266K | Buy |
883
+75
| +9% | +$23.9K | 0.04% | 388 |
|
|
2018
Q3 | $286K | Buy |
808
+21
| +3% | +$7.23K | 0.03% | 433 |
|
|
2018
Q2 | $229K | Buy |
787
+37
| +5% | +$10.4K | 0.03% | 486 |
|
|
2018
Q1 | $205K | Buy |
750
+10
| +1% | +$3.1K | 0.03% | 530 |
|
|
2017
Q4 | $236K | Buy |
740
+15
| +2% | +$4.81K | 0.03% | 471 |
|
|
2017
Q3 | $228K | Buy |
+725
| New | +$215K | 0.03% | 462 |
|
|
2017
Q1 | – | Sell |
-825
| Closed | -$235K | – | 524 |
|
|
2016
Q4 | $235K | Hold |
825
| – | – | 0.04% | 441 |
|
|
2016
Q3 | $259K | Sell |
825
-175
| -18% | -$51.8K | 0.04% | 419 |
|
|
2016
Q2 | $242K | Buy |
+1,000
| New | +$264K | 0.04% | 415 |
|
|
2016
Q1 | – | Sell |
-715
| Closed | -$218K | – | 527 |
|
|
2015
Q4 | $218K | Hold |
715
| – | – | 0.04% | 426 |
|
|
2015
Q3 | $211K | Sell |
715
-43
| -6% | -$14.2K | 0.04% | 443 |
|
|
2015
Q2 | $306K | Buy |
758
+3
| +0.4% | +$1.2K | 0.05% | 379 |
|
|
2015
Q1 | $318K | Buy |
755
+115
| +18% | +$45.3K | 0.05% | 365 |
|
|
2014
Q4 | $217K | Sell |
640
-50
| -7% | -$16.2K | 0.04% | 434 |
|
|
2014
Q3 | $229K | Hold |
690
| – | – | 0.04% | 442 |
|
|
2014
Q2 | $217K | Hold |
690
| – | – | 0.04% | 463 |
|
|
2014
Q1 | $211K | Buy |
+690
| New | +$219K | 0.05% | 330 |
|
Other funds holding BIIB
VCM
VPM
Moors & Cabot's BIIB Position: Q1 2026 in Review
Moors & Cabot increased its Biogen (BIIB) stake by 10% in Q1 2026, buying an estimated $28.4K and bringing the position to 1,653 shares worth $303K. The position accounts for 0.01% of the portfolio, ranked #698.
Moors & Cabot first reported a position in BIIB in Q1 2014 and has held it in 33 quarters since. The position peaked at $318K in Q1 2015. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Moors & Cabot held 1,653 shares of Biogen worth $303K as of Q1 2026.
- Moors & Cabot bought 154 Biogen shares in Q1 2026, an estimated $28.4K.
- Biogen made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #698 holding.
- Moors & Cabot first reported a position in Biogen in Q1 2014 and has held it in 33 quarters since.
- Moors & Cabot's Biogen position peaked at $318K in Q1 2015.
- 1,008 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.